Profiling of B cells and their subsets by whole blood gene expression analysis versus flow cytometry in multiple sclerosis

Sahla El Mahdaoui; Marina Rode von Essen; Marie Mathilde Hansen; Jeppe Romme Christensen; Finn Sellebjerg; Helle Bach Søndergaard

doi:10.1016/j.msard.2024.105898

Profiling of B cells and their subsets by whole blood gene expression analysis versus flow cytometry in multiple sclerosis

Sahla El Mahdaoui^*, Marina Rode von Essen, Marie Mathilde Hansen, Jeppe Romme Christensen, Finn Sellebjerg, Helle Bach Søndergaard

^*Corresponding author for this work

Department of Neurology

Abstract

We investigated if differentially expressed mRNA targets could be used as surrogate markers for circulating B cells and subsets. In paired blood samples from patients with untreated, anti-CD20-treated, fingolimod-treated, and natalizumab-treated multiple sclerosis, whole blood expression of CD19 correlated with B cell counts determined by flow cytometry, ROR1 with transitional B cells, TCL1A and ZNF727 with naïve B cells, NEXMIF with memory B cells and BCMA with plasmablasts. CD19 expression distinguished patients with B cell repletion and may be used as an alternative to flow cytometry, but NEXMIF was unsuitable for memory B cell monitoring in rituximab-treated patients.

Original language	English
Article number	105898
Journal	Multiple Sclerosis and Related Disorders
Volume	91
ISSN	2211-0348
DOIs	https://doi.org/10.1016/j.msard.2024.105898
Publication status	Published - 2024

Keywords

Anti-CD20
Cell sorting
Extended interval dosing
Infusion
Microarray

Access to Document

10.1016/j.msard.2024.105898

Cite this

@article{aad2b1440bb84e379273d68534df7ce6,

title = "Profiling of B cells and their subsets by whole blood gene expression analysis versus flow cytometry in multiple sclerosis",

abstract = "We investigated if differentially expressed mRNA targets could be used as surrogate markers for circulating B cells and subsets. In paired blood samples from patients with untreated, anti-CD20-treated, fingolimod-treated, and natalizumab-treated multiple sclerosis, whole blood expression of CD19 correlated with B cell counts determined by flow cytometry, ROR1 with transitional B cells, TCL1A and ZNF727 with na{\"i}ve B cells, NEXMIF with memory B cells and BCMA with plasmablasts. CD19 expression distinguished patients with B cell repletion and may be used as an alternative to flow cytometry, but NEXMIF was unsuitable for memory B cell monitoring in rituximab-treated patients.",

keywords = "Anti-CD20, Cell sorting, Extended interval dosing, Infusion, Microarray",

author = "{El Mahdaoui}, Sahla and {von Essen}, {Marina Rode} and Hansen, {Marie Mathilde} and {Romme Christensen}, Jeppe and Finn Sellebjerg and S{\o}ndergaard, {Helle Bach}",

note = "Copyright {\textcopyright} 2024. Published by Elsevier B.V.",

year = "2024",

doi = "10.1016/j.msard.2024.105898",

language = "English",

volume = "91",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier",

}

TY - JOUR

T1 - Profiling of B cells and their subsets by whole blood gene expression analysis versus flow cytometry in multiple sclerosis

AU - El Mahdaoui, Sahla

AU - von Essen, Marina Rode

AU - Hansen, Marie Mathilde

AU - Romme Christensen, Jeppe

AU - Sellebjerg, Finn

AU - Søndergaard, Helle Bach

PY - 2024

Y1 - 2024

N2 - We investigated if differentially expressed mRNA targets could be used as surrogate markers for circulating B cells and subsets. In paired blood samples from patients with untreated, anti-CD20-treated, fingolimod-treated, and natalizumab-treated multiple sclerosis, whole blood expression of CD19 correlated with B cell counts determined by flow cytometry, ROR1 with transitional B cells, TCL1A and ZNF727 with naïve B cells, NEXMIF with memory B cells and BCMA with plasmablasts. CD19 expression distinguished patients with B cell repletion and may be used as an alternative to flow cytometry, but NEXMIF was unsuitable for memory B cell monitoring in rituximab-treated patients.

AB - We investigated if differentially expressed mRNA targets could be used as surrogate markers for circulating B cells and subsets. In paired blood samples from patients with untreated, anti-CD20-treated, fingolimod-treated, and natalizumab-treated multiple sclerosis, whole blood expression of CD19 correlated with B cell counts determined by flow cytometry, ROR1 with transitional B cells, TCL1A and ZNF727 with naïve B cells, NEXMIF with memory B cells and BCMA with plasmablasts. CD19 expression distinguished patients with B cell repletion and may be used as an alternative to flow cytometry, but NEXMIF was unsuitable for memory B cell monitoring in rituximab-treated patients.

KW - Anti-CD20

KW - Cell sorting

KW - Extended interval dosing

KW - Infusion

KW - Microarray

UR - http://www.scopus.com/inward/record.url?scp=85204645096&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2024.105898

DO - 10.1016/j.msard.2024.105898

M3 - Journal article

C2 - 39317145

SN - 2211-0348

VL - 91

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

M1 - 105898

ER -

Profiling of B cells and their subsets by whole blood gene expression analysis versus flow cytometry in multiple sclerosis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this